Amrinone


Concise Prescribing Info
Indications/Uses
Heart failure.
Dosage/Direction for Use
Adult : IV Loading dose: 750 mcg/kg via slow inj, may repeat dose 30 mins later if needed. Maintenance: 5-10 mcg/kg/min via infusion. Max cumulative: 10 mg/kg in 24 hr.
Dosage Details
Intravenous
Heart failure
Adult: Loading dose: 750 mcg/kg by slow inj over 2-3 min (may be repeated after 30 minutes if necessary). Maintenance: 5-10 mcg/kg/min by infusion. Max cumulative dose: 10 mg/kg in 24 hr.
Incompatibility
Incompatible with glucose-containing solutions and furosemide.
Contraindications
Hypersensitivity.
Special Precautions
Obstructive pulmonary or aortic disease, hypertrophic cardiomyopathy; BP and heart rate monitored during drug administration; fluid and electrolyte balance should be maintained; platelet counts and liver function should be monitored; protect amp from light. Pregnancy and lactation.
Adverse Reactions
GI disturbances, nausea, vomiting, thrombocytopaenia, hypotension, chest pain, hypersensitivity, myositis, vasculitis, nail discoloration, Inj site pain, decreased tear production.
Potentially Fatal: Cardiac arrhythmia, hepatotoxicity.
IV/Parenteral: C
Overdosage
May result in severe hypotension. General supportive and symptomatic treatment, including circulatory support, should also be initiated as necessary.
Drug Interactions
Chemical interaction with precipitation occurs with amrinone and dextrose or furosemide. Thus drug mixing should be avoided.
Potentially Fatal: Concurrent usage with disopyramide may lead to severe hypotension.
Action
Description: Amrinone is a phosphodiesterase inhibitor which has vasodilating and positive inotropic properties. It causes an increase in cyclic adenosine monophosphate conc leading to greater contractile force in cardiac muscle.
Pharmacokinetics:
Distribution: 10-22% bound to plasma proteins. Half-life after IV admin: 4-6 hr.
Metabolism: Partially metabolised in liver.
Excretion: 40% excreted unchanged.
Storage
Store at 15-30°C.
MIMS Class
Disclaimer: This information is independently developed by MIMS based on Amrinone from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in